A drug currently in clinical trials for Alzheimer's disease, LM11A-31, has demonstrated a 50% reduction in the progression of cognitive decline, as measured by ADAS-cog13 and MMSE scores, compared to placebo in its Phase 2a study. Dr. Frank Longo, co-founder of PharmatrophiX, the company developing the drug, recently discussed these promising developments. The findings were further supported by new analyses presented at the Alzheimer's Association International Conference (AAIC) in London, highlighting the drug's impact on brain network function.
LM11A-31, also known as C-31, is an orally administered small molecule developed by Dr. Longo, a professor at Stanford School of Medicine. Unlike many existing Alzheimer's treatments that primarily target amyloid plaques, LM11A-31 operates by modulating the p75 neurotrophin receptor, aiming to protect neurons and slow the progression of neurodegeneration through multiple mechanisms. This approach offers a broader intervention against the complex pathology of Alzheimer's.
The Phase 2a trial, which involved 242 participants with mild to moderate Alzheimer's disease, concluded in June 2020. Results, published in Nature Medicine in 2024, confirmed the drug's safety and tolerability. The study also revealed significant beneficial effects across five biomarker categories, including structural MRI, FDG-PET scans, and cerebrospinal fluid (CSF) markers for synaptic and glial health, as well as plasma p-tau217.
Recent analysis presented at the AAIC in July 2026 further indicated that LM11A-31 significantly slowed the decline in brain network connectivity. This suggests the drug helps maintain the integrity of communication networks within the brain, which are crucial for cognitive functions like memory. "LM11A-31 is designed to protect the synapses – the connections between neurons – that enable the brain to function as an integrated network," Dr. Longo stated in an announcement from PharmatrophiX and Indiana University.
PharmatrophiX is now planning a definitive Phase 2b/3 clinical trial to further evaluate LM11A-31. The drug's multi-faceted mechanism, which includes inhibiting tau accumulation and reducing inflammation, positions it as a potential breakthrough in a field where effective treatments remain limited. The company is also exploring LM11A-31's potential in other neurodegenerative conditions, including Progressive Supranuclear Palsy (PSP), with a multicenter study for PSP initiating in June 2026.
